Matches in DBpedia 2014 for { ?s ?p Dapagliflozin (INN/USAN, trade name Farxiga in the US and Forxiga in the EU) is a drug used to treat type 2 diabetes. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca. Although dapagliflozin's method of action would operate on both types of diabetes and other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with type 1 diabetes.In July 2011 a US Food and Drug Administration (FDA) committee recommended against approval until more data were available. The FDA approved dapagliflozin on January 8, 2014 for glycemic control, along with diet and exercise, in adults with type 2 diabetes.In April 2012, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion on the drug. It is now marketed in a number of European countries including the UK and Germany.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Dapagliflozin abstract "Dapagliflozin (INN/USAN, trade name Farxiga in the US and Forxiga in the EU) is a drug used to treat type 2 diabetes. It was developed by Bristol-Myers Squibb in partnership with AstraZeneca. Although dapagliflozin's method of action would operate on both types of diabetes and other conditions resulting in hyperglycemia, the current clinical trials specifically exclude participants with type 1 diabetes.In July 2011 a US Food and Drug Administration (FDA) committee recommended against approval until more data were available. The FDA approved dapagliflozin on January 8, 2014 for glycemic control, along with diet and exercise, in adults with type 2 diabetes.In April 2012, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion on the drug. It is now marketed in a number of European countries including the UK and Germany.".